ICON PLC Files 6-K for Q2 2024

TL;DR

ICON PLC dropped its Q2 2024 6-K, check the numbers vs last year.

AI Summary

ICON PLC filed a 6-K report on July 25, 2024, for the period ending June 30, 2024. The filing includes financial data for the second quarter of 2024 and the first six months of the year, comparing it to the same periods in 2023. Specific financial figures such as revenue, net income, and earnings per share for these periods are detailed within the report.

Why It Matters

This filing provides investors with updated financial performance data for ICON PLC, crucial for assessing the company's recent operational results and making informed investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) providing updated financial information, not a significant event like an acquisition or major regulatory change.

Key Numbers

• Q2 2024 — Reporting Period (Financial results for the second quarter of 2024 are detailed.)
• First six months of 2024 — Reporting Period (Financial results for the first half of 2024 are detailed.)

Key Players & Entities

• ICON PLC (company) — Filer of the report
• 20240630 (date) — End of reporting period
• 20240725 (date) — Filing date

FAQ

Key Financial Figures

• $2 billion — ly-owned subsidiary of ICON plc, issued $2 billion of Senior Secured Notes ("the New Notes
• $750 million — sued in aggregate principal amounts of: $750 million 5.809% Senior Secured Notes due 2027 (t
• $500 million — d Notes due 2029 (the "2029 Notes") and $500 million 6.000% Senior Secured Notes due 2034 (t
• $5,515 million — a senior secured term loan facility of $5,515 million and a senior secured revolving credit f
• $300 million — ility in an initial aggregate amount of $300 million (subsequently increased on May 2, 2023
• $2,014.9 million — g mandatory and voluntary repayments of $2,014.9 million (six months ended June 30, 2024: $2,289
• $2,289.9 million — illion (six months ended June 30, 2024: $2,289.9 million) of the senior secured term loan facili
• $14.9 million — ted with previously capitalized fees of $14.9 million (six months ended June 30, 2024: $16.9
• $16.9 million — illion (six months ended June 30, 2024: $16.9 million) . In addition, during the quarter en
• $143.0 million — ed June 30, 2024, the Company drew down $143.0 million (six months ended June 30, 2024: $193.0
• $193.0 million — illion (six months ended June 30, 2024: $193.0 million) of the senior secured revolving loan f
• $248.0 million — illion (six months ended June 30, 2024: $248.0 million). Refer to note 10. Bank credit lines a

Filing Documents

• iclr-20240630.htm (6-K) — 1222KB
• icon-ex22guarantorschedule.htm (EX-22.1) — 99KB
• 0001060955-24-000066.txt ( ) — 7317KB
• iclr-20240630.xsd (EX-101.SCH) — 54KB
• iclr-20240630_cal.xml (EX-101.CAL) — 77KB
• iclr-20240630_def.xml (EX-101.DEF) — 267KB
• iclr-20240630_lab.xml (EX-101.LAB) — 532KB
• iclr-20240630_pre.xml (EX-101.PRE) — 438KB
• iclr-20240630_htm.xml (XML) — 1068KB

Business

Business ICON is a contract research organization ("CRO"), providing outsourced services on a global basis to pharmaceutical, biotechnology, medical device and government and public health organizations. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies. Our vision is to be the healthcare intelligence partner of choice by delivering industry leading solutions and best in class performance in clinical development. We believe that we are one of a select group of CROs with the expertise and capability to conduct clinical trials in the major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated "full service" solution. At June 30, 2024 we had approximately 41,100 employees in 97 locations in 55 countries. During the six months ended June 30, 2024, we derived 38.0%, 50.6% and 11.4% of our revenue in the United States, Europe and Rest of World respectively (during the six months ended June 30, 2023: 42.4% , 47.3% and 10.3% respectively). We began operations in 1990 and have expanded our business through organic growth, together with a number of strategic acquisitions to enhance our capabilities and expertise in certain areas of the clinical development process. We are incorporated in Ireland and our principal executive office is located at: South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Republic of Ireland. The contact telephone number of this office is +353-1-291-2000. Recent developments Changes in Board of Directors composition On July 23, 2024, Ms. Joan Garahy retired from the Board of Directors and Ms. Anne Whitaker was appointed to the Board of Directors. Executive Leadership transition On April 3, 2024, the Company announced that Chief Financial Officer ("CFO"), Mr. Brendan Brennan, will l

View Full Filing

View this 6-K filing on SEC EDGAR